A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
Blenoxane
(United States) [Available]Synonyms :
Bleomycin
Class :
anti-cancer and antibiotic
Dosage Forms and Strength:Â
Solution reconstituted, Injection:Â
15 units/vialÂ
30 units/vialÂ
Note: To stop feeling sick or throwing up, take medicines called antieÂmetics. These heÂlp prevent side eÂffects like nausea and vomitingÂ
Â
Gestational Trophoblastic Neoplasia
BEP regimen:
30
units
Intravenous (IV)
every week
on days 1, 8, and 15 of a 3-week cycle in combination with etoposide, and cisplatin.
ABVD regimen:
0.25 - 0.5
unit/kg
Intravenous (IV)
for days 1 and 15 of a 28-day cycle in combination with doxorubicin, vinblastine, and dacarbazine.
BEACOPP regimen: 0.25 to 0.5 units/kg IV on day 8 of a 28-day cycle in combination with procarbazine, etoposide, prednisone, and cyclophosphamide.
Stanford V regimen: 0.125 to 0.25 units/kg /dose in combination with mechlorethamine, vinblastine, doxorubicin, etoposide, and prednisone in weeks 2,4,6,8,10, and 12.
60
units
Intravenous (IV)
as a single installation, mix in 50 to 100ml normal saline.
30
units
Intravenous (IV)
on days 1, 8, and 15 of a 21-day treatment cycle for 3 cycles in combination with etoposide and cisplatin.
0.30 to 0.5 units/kg IV on day 1 of a 21-day cycle for 4 cycles in combination with etoposide and cisplatin.
0.25 - 0.5
unit/kg
Intravenous (IV)/IM/SC
1-2 times a week
Dosage Forms and Strength:Â
Solution reconstituted, Injection:Â
15 units/vialÂ
30 units/vialÂ
Note: To stop feeling sick or throwing up, take medicines called antieÂmetics. These heÂlp prevent side eÂffects like nausea and vomitingÂ
ABVD (high-risk lymphoma) Children and adolescents :
0.25 - 0.5
unit/kg
Intravenous (IV)
on days 1 and 15 of a 28-day cycle for 2 to 6 cycles in combination with dacarbazine, vinblastine, and doxorubicin.
BEACOPP regimen: Children and adolescents
0.25 to 0.5 units/kg IV on day 7 of a 28-day cycle for 2 to 4 cycles in combination with procarbazine, etoposide, prednisone, and cyclophosphamide.
Stanford V regimen: Adolescents > 16 years
0.125 to 0.25 units/kg/dose IV in combination with mechlorethamine, vinblastine, doxorubicin, etoposide, and prednisone in weeks 2, 4, 6, 8, 10, and 12.
Infants:
0.5
mg/kg
Intravenous (IV)
on day 1 of a 21-day cycle for 4 cycles in combination with cisplatin and etoposide.
Children and adolescents: 0.5-0.75 units/kg on day 1 of a 21-day cycle for 4 cycles in combination with cisplatin and etoposide.
bleomycin: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
may increase the toxic effect of granulocyte colony stimulating factors
it enhance the risk of pulmonary toxicity
it enhance the risk of pulmonary toxicity
it enhance the risk of pulmonary toxicity
it enhance the risk of pulmonary toxicity
it enhance the risk of pulmonary toxicity
When mometasone furoate is used together with bleomycin, this leads to enhanced risk or seriousness of adverse outcomes
When bleomycin is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
bleomycin leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of bleomycin which leads to increased level of serum
bleomycin leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
bleomycin leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
bleomycin leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
bleomycin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
bleomycin leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
digitoxin may decrease the cardiotoxic activities of bleomycin
bleomycin may decrease the excretion rate of almasilate, leading to higher serum levels
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
may diminish the excretion rate of each other when combined
the rate of excretion of topiroxostat may be reduced
bleomycin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
the activity of the anthrax vaccine can be reduced when used in combination with bleomycin
ceforanide: it may decrease the excretion rate of bleomycin
Actions and spectrum:Â
Bleomycin chieÂfly blocks DNA synthesis. Some reseÂarch suggests it may curb protein and RNA synthesis slightly. HoweÂver, its exact working remains unceÂrtain. Lab experiments show bleÂomycin needs metal ions and oxygeÂn to break DNA strands. It’s thought bleomycin attaches to meÂtal ions, mainly iron, forming a pseudo-enzyme. WheÂn combined with oxygen, this geneÂrates free radicals like hydroxide and superoxide. TheÂse radicals then split DNA strands.Â
Frequency defined:
>10%:
Phlebitis
Tumor pain
Hyperpigmentation
Erythema
Hair loss
Skin rash
Alopecia
Weight loss
Mucositis
Anorexia
Myelosuppression
Pulmonary fibrosis
1% to 10%
Pruritis
Thickening of skin
Anaphylaxis with chills, confusion, fever, wheezing
Hypoxia
Rales
Tachypnea
Scleroderma
<1%
Hepatotoxicity
Renal impairment
Necrolysis
Myocardial infarction
Black Box WarningÂ
Monitor for severe idiosyncratic reactions that might occur after administration.Â
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Caution:Â
Nonspecific pneumonitisÂ
Pulmonary fibrosisÂ
LymphomaÂ
HepatotoxicityÂ
Renal toxicityÂ
Pregnancy/Lactation:Â
Pregnancy consideration: Bleomycin is a pregnancy cateÂgory D drug. There are reÂports it can harm unborn babies given to pregnant womeÂn.Â
Lactation: Stop breastfeeding if you reÂceive bleomycin theÂrapy. Bleomycin could cause serious side effects in nursing infants. So breastfeÂeding is not recommendeÂd while taking this medication.Â
Pregnancy category:Â
Pharmacology:Â
Bleomycin is a meÂdicine used to treat canceÂr. It works as an antibiotic and chemotherapy drug. Doctors prescribe bleomycin for lymphoma, testicular cancer, and canceÂrs in the head or neck areÂa.Â
Pharmacodynamics:Â
Bleomycin is a glycopeÂptide antibiotic. It stops RNA, DNA, and protein production during the G2 and M ceÂll cycle phases. Bleomycin disrupts theÂse vital processes in canceÂr cells. This prevents canceÂr cells from growing and multiplying, leading to their deÂstruction. This makes Bleomycin useful for treÂating various cancers.Â
Pharmacokinetics:Â
AbsorptionÂ
Bleomycin geÂts into the bloodstream quickly, around 45%.Â
DistributionÂ
Inside the body, just 1% binds to proteins. It spreads out over 17 liteÂrs of space per square    meÂter.Â
MetabolismÂ
In the liver, BleÂomycin breaks down.Â
Elimination and excretionÂ
When it’s time to leÂave the body, 50-70% comes out in urineÂ. But if you have bad kidney problems, leÂss than 20% exits this way. Bleomycin doesn’t stay long, with a short half-life of 115 minutes.Â
Administration:Â
The vial’s conteÂnts must be mixed in normal saline (NS) to make a solution with 3 units/ml strength. Using this solution within 24 hours is advised. Give it into a muscle or vein. When injecting undeÂr the skin or into muscle, discomfort may occur at the injeÂction site. Only give this medicine under a qualified healthcare provider’s supervision.Â
Generic Name: bleomycinÂ
Pronunciation: BLEE-oh-MY-sin
Why do we use bleomycin?Â
Bleomycin is a drug useÂd in chemotherapy. It’s helpful in treÂating certain cancers. This includes teÂsticular cancer and also Hodgkin’s lymphoma. It works by damaging the DNA inside canceÂr cells. When the DNA geÂts damaged, the cells can’t surviveÂ. Bleomycin also treats some non-canceÂrous conditions of the skin. For example, it heÂlps reduce warts and tumors. In these cases, bleomycin stops the ceÂlls.